Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein

Biochemical and Biophysical Research Communications

Volumn 319, Issue 3, 2004, Pages 746-752

  Yuan, Kehu ^a   Yi, Ling ^a   Chen, Jian ^a   Qu, Xiuxia ^a   Qing, Tingting ^a   Rao, Xi ^a   Jiang, Pengfei ^a   Hu, Jianhe ^a   Xiong, Zikai ^a   Nie, Yuchun ^a   Shi, Xuanling ^a   Wang, Wei ^a   Ling, Chen ^a   Yin, Xiaolei ^a   Fan, Keqiang ^b   Lai, Luhua ^b   Ding, Mingxiao ^a   Deng, Hongkui ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Entry inhibitor; Peptides; Pseudotyped virus; SARS CoV; Spike protein

Indexed keywords

GLYCOPROTEIN; PEPTIDE DERIVATIVE; PROTEIN INHIBITOR;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SARS CORONAVIRUS; SCREENING; SEQUENCE ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME; VALIDATION PROCESS; WILD TYPE;

AMINO ACID SEQUENCE; BIOLOGICAL ASSAY; CELL LINE; CIRCULAR DICHROISM; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SARS VIRUS; VIRAL ENVELOPE PROTEINS;

SARS COV;

EID: 2942594156     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.05.046     Document Type: Article

References (34)

1. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., Lam W.K., Seto W.H., Yam L.Y., Cheung T.M., Wong P.C., Lam B., Ip M.S., Chan J., Yuen K.Y., Lai K.N. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348:2003;1977-1985
2. Poutanen S.M., Low D.E., Henry B., Finkelstein S., Rose D., Green K., Tellier R., Draker R., Adachi D., Ayers M., Chan A.K., Skowronski D.M., Salit I., Simor A.E., Slutsky A.S., Doyle P.W., Krajden M., Petric M., Brunham R.C., McGeer A.J. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348:2003;1995-2005
3. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 300:2003;1394-1399
4. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:2003;1967-1976
5. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., Roper R.L. The Genome sequence of the SARS-associated coronavirus. Science. 300:2003;1399-1404
6. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426:2003;450-454
7. Wang P., Chen J., Zheng A., Nie Y., Shi X., Wang W., Wang G., Luo M., Liu H., Tan L., Song X., Wang Z., Yin X., Qu X., Wang X., Qing T., Ding M., Deng H. Expression cloning of functional receptor used by SARS coronavirus. Biochem. Biophys. Res. Commun. 315:2004;439-444
8. Moore J.P., Doms R.W. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. USA. 100:2003;10598-10602
9. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:2001;777-810
10. Weissenhorn W., Dessen A., Calder L.J., Harrison S.C., Skehel J.J., Wiley D.C. Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol. 16:1999;3-9
11. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:2000;531-569
12. Bentz J. Membrane fusion mediated by coiled coils: a hypothesis. Biophys. J. 78:2000;886-900
13. Lamb R.A., Joshi S.B., Dutch R.E. The paramyxovirus fusion protein forms an extremely stable core trimer: structural parallels to influenza virus haemagglutinin and HIV-1 gp41. Mol. Membr. Biol. 16:1999;11-19
14. Peisajovich S.G., Shai Y. New insights into the mechanism of virus-induced membrane fusion. Trends Biochem. Sci. 27:2002;183-190
15. Watanabe S., Takada A., Watanabe T., Ito H., Kida H., Kawaoka Y. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74:2000;10194-10201
16. Bosch B.J., van der Zee R., de Haan C.A., Rottier P.J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77:2003;8801-8811
17. Root M.J., Kay M.S., Kim P.S. Protein design of an HIV-1 entry inhibitor. Science. 291:2001;884-888
18. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1998;1302-1307
19. Imai M., Okada N., Okada H. Inhibition of HIV-1 infection by an intramolecular antisense peptide to T20 in gp160. Microbiol. Immunol. 44:2000;205-212
20. Wong S.K., Li W., Moore M.J., Choe H., Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279:2004;3197-3201
21. Xiao X., Chakraborti S., Dimitrov A.S., Gramatikoff K., Dimitrov D.S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312:2003;1159-1164
22. Wang E., Sun X., Qian Y., Zhao L., Tien P., Gao G.F. Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion. Biochem. Biophys. Res. Commun. 302:2003;469-475
23. Kliger Y., Levanon E.Y. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy. BMC Microbiol. 3:2003;20
24. Spiga O., Bernini A., Ciutti A., Chiellini S., Menciassi N., Finetti F., Causarono V., Anselmi F., Prischi F., Niccolai N. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem. Biophys. Res. Commun. 310:2003;78-83
25. Singh M., Berger B., Kim P.S. LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteins. J. Mol. Biol. 290:1999;1031-1041
26. Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. USA. 2004
27. Yuchun Nie, Guangwen Wang, Xuanling Shi, Hong Zhang, Yan Qiu, Zhongping He, Wei Wang, Gewei Lian, L.D. Xiaolei Yin, Lili Ren, Jianwei Wang, Xiong He, Taisheng Li, Hongkui Deng, M. Ding, Neutralizing antibodies in the SARS-CoV-infected patients, J. Infect. Dis. (2004) in press
28. Hong Zhang, Guangwen Wang, Jian Li, Yuchun Nie, Xuanling Shi, Gewei Lian, Wei Wang, Xiaolei Yin, Yang Zhao, Xiuxia Qu, M. Ding, H. Deng, Identification of an antigenic determinant on the S2 domain of the SARS-CoV spike glycoprotein capable of inducing neutralizing antibodies, J. Virol. (2004) in press
29. Hussain R.F., Nouri A.M., Oliver R.T. A new approach for measurement of cytotoxicity using colorimetric assay. J. Immunol. Methods. 160:1993;89-96
30. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA. 91:1994;9770-9774
31. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1995;1075-1082
32. Liu S., Xiao G., Chen Y., He Y., Niu J., Escalante C.R., Xiong H., Farmar J., Debnath A.K., Tien P., Jiang S. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 363:2004;938-947
33. Tripet B., Howard M.W., Jobling M., Holmes R.K., Holmes K.V., Hodges R.S. Structural characterization of the SARS-coronavirus spike S fusion protein core. J. Biol. Chem. 2004;. in press
34. Dwyer J.J., Hasan A., Wilson K.L., White J.M., Matthews T.J., Delmedico M.K. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry. 42:2003;4945-4953